Ipamorelin and CJC-1295 are two of the most studied growth hormone research peptides. They both raise GH levels, but they pull on different levers, which is why researchers often examine them side by side.
How GH Release Is Controlled
The pituitary gland releases growth hormone in pulses. Two upstream signals shape those pulses. Growth hormone-releasing hormone (GHRH) tells the pituitary how big a pulse should be. Ghrelin, working through the ghrelin receptor (GHS-R1a), tells it when to fire.
This two-input design is why a single peptide rarely captures the full picture. Ipamorelin works on one input. CJC-1295 works on the other.
Ipamorelin: A Selective Ghrelin Mimic
Ipamorelin is a small peptide, only five amino acids long. It is a selective agonist of the ghrelin receptor GHS-R1a. In simple terms, it copies the GH-releasing signal of ghrelin without the rest of ghrelin's effects.
The selectivity is what made ipamorelin interesting in early research. Older ghrelin-mimetics tended to also raise cortisol and prolactin, two stress and lactation hormones, and to stimulate appetite. Ipamorelin was characterized as releasing GH without those off-target signals (Raun et al., 1998).
CJC-1295: A GHRH Analog
CJC-1295 is a longer peptide, 30 amino acids, designed as an analog of GHRH. It binds the GHRH receptor and amplifies the size of GH pulses by acting on the same input that the body's own GHRH uses.
There are two versions in the research literature. The "no DAC" form, often called Mod GRF 1-29, has a short half-life and is the form used most often in mechanism studies. The "with DAC" form contains a Drug Affinity Complex that binds blood albumin, extending the half-life from minutes to days. The two versions answer different research questions.
Why Researchers Study Them Together
Because ipamorelin and CJC-1295 act on different receptors, combining them engages both inputs to the pituitary at the same time. CJC-1295 sets the size of the pulse through the GHRH receptor. Ipamorelin triggers the release event through the ghrelin receptor.
The combined effect on GH release is greater than either peptide alone. This is why head-to-head comparisons usually appear alongside combined-administration studies in the literature.
Open questions include how the two pathways interact at the receptor and intracellular level, how pulse timing affects downstream IGF-1 patterns, and how the "with DAC" pharmacokinetics shape long-term GH dynamics in research models. These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.